What to Know About This Fund's $74.8 Million Indivior Sale

Impact · against what's priced in

Indivior's upward guidance revision and record EBITDA provide a strong bullish catalyst, offsetting the noise of institutional profit-taking. The company's acceleration in SUBLOCADE sales demonstrates fundamental momentum that outweighs the impact of a single fund's divestment.

INDV+0.60

No priced-in read yet

In context

The company raised 2026 revenue guidance to up to $1.29 billion and adjusted EBITDA to $660 million, supported by a 32% jump in SUBLOCADE sales and a record Q1 adjusted EBITDA of $164 million.

Read from the article alone

• guidance
• earnings
• pharmaceuticals
• healthcare
• INDV
• institutional trading
• opioid treatment
• profit taking
• sec filing

Search tags